SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is facing intense volatility and a massive sell-off after Marvell canceled purchase orders linked to Celestial AI, citing a confidentiality breach by management. The community is sharply divided between investors demanding management accountability for the delayed disclosure of this news and those betting on a recovery based on the company's underlying optical technology.

Lucid Group, Inc. manufactures electric vehicles. It designs, develops, and builds energy storage systems for electric vehicles and supplies automakers with the battery pack system needed to power hybrid, plug-in, and electric vehicles. The company was founded in December 2007 and is headquartered in Newark, CA.

Lucid Group Inc

Lucid Group Inc. is experiencing intense selling pressure and record-low valuations, leaving investors deeply divided between those viewing the current price as a long-term bargain due to PIF and Uber backing and those fearing further dilution, a potential reverse split, or even bankruptcy. The community is heavily focused on the disconnect between the company's high-performance vehicle technology and its ongoing struggle to sustain share price momentum amid persistent capital burn.

Joby Aviation, Inc. is a transportation company, which engages in developing an all-electric, vertical take-off and landing aircraft that intends to operate as a commercial passenger aircraft. The company was founded by Bevirt Joebenn in 2009 and is headquartered in Santa Cruz, CA.

Joby Aviation Inc

Joby Aviation is capturing significant community attention following the successful completion of historic point-to-point air taxi demonstration flights in New York City. Investors are closely monitoring the company's transition from prototype testing to real-world infrastructure integration as they progress through critical FAA certification phases.

Moolec Science SA engages in the development and production of science-based food ingredients. Its products include pet food, animal feed, and dietary supplements. It operates through the following segments: Seed and Integrated Products, Crop Protection, Crop Nutrition, and Emerging Solutions. The company was founded by Gastón Paladini, Henk Hoogenkamp, and Martin Salinas in 2020 and is headquartered in George Town, Cayman Islands.

Moolec Science SA

Moolec Science SA is trending due to a breakthrough in molecular farming involving the successful expression of bovine myoglobin in pea seeds, fueling investor excitement and high-volume trading activity. While bullish community members point to the potential for a massive short squeeze given the stock's low float, skeptics are actively debating the company's financials, dilution history, and the sustainability of the price surge.

Bed Bath & Beyond, Inc. engages in the provision of an e-commerce platform. It offers furniture and home furnishing products and services. The company was founded on May 5, 1997 and is headquartered in Murray, UT.

Bed Bath & Beyond Inc.

Bed Bath & Beyond Inc

Bed Bath & Beyond is trending as investors react to the company's first revenue growth in 19 quarters and a strategic shift toward an 'Everything Home' marketplace. Community discussions are heavily divided, with some traders highlighting the operational turnaround and bullish technical setups, while skeptics remain focused on the company's past struggles and ongoing cash burn.

Orca is the most user-friendly DEX on Solana.  Orca is one of the first general-purpose AMMs launched on Solana. Users can swap assets, provide liquidity, and earn yield through an easy-to-use interface. Projects can use Orca as a money-lego to easily integrate swapping, farming, or on-chain data into their dApp.  Orca strives to provide easy and effective financial tools for everyone, bringing DeFi to the masses.

Orca

Orca is seeing significant volatility and community interest, driven by its role as a leading decentralized exchange on Solana and speculation regarding DAO-led buyback programs. Traders are actively debating its potential for a short squeeze and price appreciation, while monitoring its performance against broader market movements and platform integrations.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

NVIDIA is surging to new all-time highs as massive institutional liquidity continues to concentrate in the stock, solidifying its position as the primary infrastructure backbone of the AI sector. While some market participants debate potential overvaluation or volatility risks, the community is heavily focused on the company's compounding dominance, sustained capex demand, and the strength of the bullish momentum leading into upcoming earnings.

High-Trend International Group is a holding company. It engages in shipping decarbonization and carbon asset management platforms. The company was founded in 2021 and is headquartered in Singapore.

High-Trend International Group. - Ordinary Shares - Class A

High-Trend International Group is experiencing significant momentum and extreme volatility, with the community actively debating whether the move is a sustainable squeeze or a high-risk pump and dump. Traders are closely monitoring key technical levels and volume spikes, with many citing the stock's low float as the primary catalyst for its rapid, multi-day price fluctuations.

Edesa Biotech, Inc. is a biopharmaceutical company, which focuses on acquisition, development, and commercialization of drug candidates for medical dermatology and respiratory diseases. Its clinical studies include EB05 for Acute Respiratory Distress Syndrome (ARDS), EB07 for systemic sclerosis (SSc), EB01 for chronic Allergic Contact Dermatitis (ACD), and EB06 for vitiligo. The company was founded by Pardeep Nijhawan on June 12, 2007 and is headquartered in Markham, Canada.

Edesa Biotech Inc

Edesa Biotech is trending as investors react to positive Phase 3 clinical momentum and heavy institutional accumulation from notable funds, fueling speculation regarding a potential buyout or strategic partnership. Community discussion is dominated by the stock's significant move on high volume, with many focusing on the low effective float and the company's lack of debt as potential catalysts for further upward volatility.

MaxLinear, Inc. engages in the provision of communications systems-on-chip (SoC) solutions used in broadband, mobile and wireline infrastructure, data center, and industrial and multi-market applications. Its products include cable broadband modems and gateways, wireline connectivity devices, radio frequency transceivers, fiber-optic modules, video set-top boxes and gateways, hybrid analog and digital televisions, direct broadcast satellite outdoor and indoor units, and power management and interface products. The company was founded by Kimihiko Imura, Curtis C. Ling, and Kishore V. Seendripu on September 25, 2003 and is headquartered in Carlsbad, CA.

MaxLinear Inc

MaxLinear is currently driving significant community engagement following a massive earnings beat and upward guidance, with many investors debating whether the stock is a legitimate AI infrastructure play or if it has reached a parabolic, overextended peak. Discussion is heavily focused on the stock's rapid momentum and the contrasting views of bulls citing strong data center growth versus bears pointing to extreme technical indicators like RSI and the likelihood of a sharp correction.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

SpringWorks Gets CHMP Nod for Mirdametinib in Rare Disease

Shares of SpringWorks Therapeutics Inc. ended over 9% higher on Thursday following a report that the company is inching closer to getting acquired by an established giant, triggering a jump in discussions among retail traders.During regular trading hours on Thursday, The Wall Street Journal reported that Merck KGaA is nearing a $3.5 billion deal to acquire SpringWorks, which specializes in rare diseases and cancer.The report, citing people familiar with the matter, noted that the German giant had&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/swtx-stock-jumps-ahead-of-q4-2024-report/ch5uuz0RwZ">confirmed</a> in February that it was in advanced talks for the buyout, and the two parties have now agreed on a price close to $47 per share.After the closing bell, Merck <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.eqs-news.com/news/ad-hoc/merck-kgaa-merck-confirms-late-stage-discussions-with-springworks-therapeutics-inc-on-potential-acquisition/b6bde507-964a-46d9-846d-9d15390345d9_en">confirmed</a> the report, saying the two parties were discussing a deal at around $47 per share. However, it added that they had neither made any final decision nor entered into a legally binding agreement.On Stocktwits, sentiment for SpringWorks jumped into the 'extremely bullish' zone, accompanied by a 657% spike in message volume.<figure class="image"><img style="aspect-ratio:1318/316;" src="https://news.stocktwits-cdn.com/SWTX_sentiment_and_message_volume_as_of_April_24_png_712d46db30.webp" alt="SWTX sentiment and message volume as of April 24.png" width="1318" height="316"><figcaption>SWTX sentiment and message volume as of April 24. | source: Stocktwits</figcaption></figure>Several watchers appeared dissatisfied with the offer, indicating some alignment with the after-hours dip on Thursday."$47 is a joke, surely?" wrote one user, adding that Pfizer should throw its hat into the ring of prospective buyers.<stembedurl>https://stocktwits.com/monoksop/message/612643957</stembedurl>However, others expressed some relief."What I get, I get. Won't be super happy or anything, but I'll take the W and move on," said one watcher.<stembedurl>https://stocktwits.com/Son_of_Shango/message/612642003</stembedurl>SpringWorks has garnered interest from suitors thanks to its lead asset, Gomekli, which treats a rare genetic disorder that causes tumor growth in nerve tissue.The company's first FDA-approved drug, Ogsiveo, is already available in the U.S. for adult desmoid tumor patients requiring systemic treatment. It raked in $61.5 million in the fourth quarter of 2024.<a href="https://stocktwits.com/symbol/SWTX">SpringWorks' stock</a> has gained over 23% this year.For updates and corrections, email newsroom[at]stocktwits[dot]com.

A person examines financial data on a screen displaying a graph with upward and downward trends, using a pen to trace the line chart. | Representative Image: Getty Images

SpringWorks Therapeutics Retail Chatter Spikes As Germany’s Merck Confirms Late-Stage Talks For $3.5B Buyout

After the closing bell, Merck said the two parties were discussing a deal at around $47 per share.

Equity

After the closing bell, Merck said the two parties were discussing a deal at around $47 per share.


SpringWorks Therapeutics springs higher as Merck KGaA takeover said close

Investing.com -- Shares of  SpringWorks Therapeutics Inc  (NASDAQ:SWTX) surged higher Thursday afternoon on reports that a potential takeover of the company by Germany’s Merck KGaA (ETR:MRCG) is getting close.

Mineralys Therapeutics Inc. (123% jump in watchers)The clinical-stage biopharmaceutical company saw the highest jump in retail interest after reporting positive topline data from its Phase 3 and Phase 2 trials for lorundrostat in treating uncontrolled hypertension (uHTN) and resistant hypertension (rHTN). Both trials met their primary efficacy endpoints, showing statistically significant blood pressure reductions.&nbsp;The company also announced a $250 million underwritten public offering to fund lorundrostat’s development and pre-commercialization efforts.Mineralys stock is up over 15% year-to-date (YTD).Tenaya Therapeutics Inc. (11% jump in watchers)Tenaya saw increased attention after reporting stronger-than-expected fourth-quarter earnings and highlighting upcoming clinical data readouts for its gene therapy programs targeting cardiomyopathies.&nbsp;CEO Faraz Ali noted continued progress in the TN-201 MyPEAK-1 and TN-401 RIDGE-1 trials.&nbsp;Tenaya’s stock remains down over 53% YTD.SpringWorks Therapeutics Inc. (10% jump in watchers)SpringWorks gained traction amid ongoing&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/swtx-sees-biggest-weekly-biotech-jump-in-stocktwits-following/cheUZARRbb2">speculation</a> about a potential buyout by Merck KGaA. While Merck confirmed advanced merger discussions in its annual report, it stopped short of announcing a deal, leaving traders searching for clues. The company’s withdrawal from a Barclays healthcare conference further fueled speculation.&nbsp;SpringWorks stock is up more than 40% YTD.COSCIENS Biopharma Inc. (9% jump in watchers)COSCIENS initiated a Phase 2a clinical efficacy trial for its avenanthramides product, which is being explored for its anti-inflammatory properties. The trial, dubbed the AvenActive study, will assess safety and efficacy in two dosage arms.&nbsp;COSCIENS stock has gained over 20% YTD.Metagenomi Inc. (7% jump in watchers)Metagenomi published new research in Nature Communications on its novel CAST gene editing system, which enables precise, programmable integration of large gene cargoes. The technology could have major implications for treating genetic diseases like cystic fibrosis and Duchenne Muscular Dystrophy.&nbsp;Metagenomi stock is down more than 46% YTD.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Hand holding test tube over stock data on computer monitor. | Image source: Getty Images

Mineralys, Tenaya, SpringWorks, COSCIENS, Metagenomi: 5 Biotech Stocks That Led Retail Follower Growth Last Week

Positive data from clinical trials, earnings readouts, M&A speculation and new research drew heavy interest from retail traders on Stocktwits for these tickers for the week ended March 14, 2025.  

SpringWorks Therapeutics (SWTX) saw the biggest retail follower increase among biotech stocks last week on Stocktwits, even as its shares tumbled more than 14%, marking their worst weekly decline since mid-January.&nbsp;Despite the drop, retail sentiment flipped to 'bullish' from 'neutral,' driven by renewed speculation about German healthcare giant Merck KGaA (MKGAY) confirming details about a buyout.<figure class="image"><img style="aspect-ratio:1316/302;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/SWTX_sentiment_and_message_volume_March_10_cba5133a09.png" alt="SWTX sentiment and message volume March 10.png" width="1316" height="302"><figcaption>SWTX sentiment and message volume March 10. | source: Stocktwits</figcaption></figure>According to The Fly, Barclays analyst Peter Lawson noted that some investors had anticipated confirmation of an acquisition from Merck's earnings report last week.&nbsp;However, Merck's annual report, published Thursday, only acknowledged that discussions about a potential merger were at an advanced stage but stated that there was no certainty a deal would be signed.&nbsp;The absence of a definitive announcement left traders analyzing the language for clues.Adding to speculation, SpringWorks canceled its planned appearance at Barclays' healthcare conference this week, continuing a pattern of event withdrawals following the FDA approval of its lead drug, Gomekli, for treating neurofibromatosis type 1 (NF1).&nbsp;The company had previously backed out of an earnings call and another public event, fueling investor theories that a significant corporate development was underway.&nbsp;Barclays maintained an 'Overweight' rating on SpringWorks, with a price target of $63. It sees limited regulatory risk to a potential Merck buyout.Retail traders on Stocktwits reacted strongly to these developments. Message volumes surged, and the company's follower count increased by 17.9%, the highest among all biotech stocks last week.&nbsp;Some investors speculated that an acquisition could be announced this week, with one suggesting a potential offer price of $120 per share — a 140% premium to SpringWorks' last closing price.&nbsp;<stembedurl>https://stocktwits.com/Aombeus/message/607327621</stembedurl>Another pointed to Merck not disclosing a termination of negotiations, which German law would have allegedly required if talks had ended, and reaffirmed their belief in SpringWorks' leadership.<stembedurl>https://stocktwits.com/TheGunnerAB/message/607292647</stembedurl>According to Koyfin, short interest in SpringWorks has declined from 15.7% at the start of the year to 12.2% last week, suggesting that bearish bets against the stock have been easing.&nbsp;The company's shares currently trade at a 47% discount to the average analyst price target of $72.88. Five of the eight analysts covering SpringWorks have a ‘Buy’rating, while three rate it a ‘Strong Buy,’ according to Koyfin.Despite last week's sharp decline, SpringWorks remains up more than 36% year-to-date.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stockbroker analyzing financial stock market with reflection on eyeglasses. Photo via Westend61 on Getty Images

SpringWorks Therapeutics Leads Biotech Pack In Weekly Retail Follower Surge: What's Fueling Interest?

Investor attention is now on whether Merck will confirm a formal offer as speculation over a potential acquisition continues dominating discussions around the stock.

SpringWorks Therapeutics Inc. (SWTX) shares surged more than 10% in Wednesday’s after-hours, signaling strong investor optimism ahead of its quarterly earnings report due after the next session.The biopharmaceutical company, focused on treatments for rare diseases and cancer, is expected to report a narrowing of fourth-quarter (Q4) adjusted losses to $0.71 per share from $1.44 a year earlier.&nbsp;Meanwhile, revenue is projected to soar to $57.16 million from $5.4 million.On Stocktwits, sentiment remained firmly bullish, though message volumes dipped slightly.The stock’s retail following grew over 2% in the past week and more than 26% in the past month.Users noted that after-hours trading volumes spiked well above the daily average, signaling heightened interest.<stembedurl>https://stocktwits.com/patten1962/message/604919223</stembedurl>One trader posted: “Yet another sleepless night ahead. I hope this is the last, and we can all celebrate.”<stembedurl>https://stocktwits.com/StrangerTrades/message/604917416</stembedurl>Recent investor enthusiasm has been fueled by&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/swtx-stock-soars-on-acquisition-buzz/ch5EgKYRtu">reports</a> that German healthcare giant Merck KGaA is in advanced talks to acquire SpringWorks. While no official confirmation has been made, there are hopes that a potential deal could be signed in the coming weeks.Last week, BofA Securities raised its price target on SWTX to $87 from $65, maintaining a Buy rating. The research firm cited FDA approval for SpringWorks’ lead asset, Gomekli, as a key growth driver.Gomekli, a MEK inhibitor, treats neurofibromatosis type 1 (NF1), a rare genetic disorder that causes tumor growth in nerve tissue.In addition, SpringWorks’ first FDA-approved drug, Ogsiveo, is already available in the U.S. for adult desmoid tumor patients requiring systemic treatment. Last month, the company pre-announced Q4 U.S. Ogsiveo sales of $61.5 million.Despite the bullish momentum, short interest on SpringWorks stock climbed from 15.7% at the start of the year to 19.4% last week, according to Koyfin data.Still, SWTX shares have surged over 53% year-to-date, far outpacing the S&amp;P 500’s 4.7% gain.For updates and corrections, email newsroom[at]stocktwits[dot]com.

SpringWorks Therapeutics Gains Retail Interest Ahead Of Q4 Earnings – What Investors Expect

Recent investor enthusiasm has been fueled by reports that German healthcare giant Merck KGaA is in advanced talks to acquire SpringWorks.

Springworks Therapeutics shares surged over 36% Monday, reaching levels last seen in mid-April 2022, as buyout speculation drove heavy trading.&nbsp;The stock is on track for its best day on record following a Reuters report that German healthcare and technology group Merck KGaA is in advanced talks to acquire the company, according to people familiar with the matter.&nbsp;If discussions are successful, a deal could be signed in the coming weeks, though neither Springworks nor Merck have commented on the report yet.Springworks is a commercial-stage biopharmaceutical company developing treatments for severe rare diseases and cancer.&nbsp;Ogsiveo, the company's first FDA-approved therapy, is used in the U.S. to treat adult patients with progressing desmoid tumors who require systemic treatment.<figure class="image"><img style="aspect-ratio:1318/324;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/SWTX_sentiment_and_message_volume_Feb_10_3b1f0e47dd.png" alt="SWTX sentiment and message volume Feb 10.png" width="1318" height="324"><figcaption>SWTX sentiment and message volume Feb 10 as of 12:10 pm ET | source: Stocktwits</figcaption></figure>On Stocktwits, sentiment for Springworks was 'extremely bullish' as message volume spiked, pushing the stock into the list of top trending symbols by late Monday morning.&nbsp;Retail traders flooded the platform with congratulatory messages for long-term holders, though some warned that a sharp pullback could occur if official statements refute the buyout rumors.<stembedurl>https://stocktwits.com/flanker30/message/603597464</stembedurl><stembedurl>https://stocktwits.com/AngusMacbeth/message/603598578</stembedurl>Last month, Springworks pre-announced fourth-quarter U.S. Ogsiveo sales of $61.5 million, exceeding TD Cowen's $57.0 million estimate and consensus expectations of $59.8 million. The brokerage had suggested that a buyout could be on the horizon.Springworks stock has risen 16% over the past 12 months. According to Koyfin data, its short interest stood at 18.4% as of the last check.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Springworks Stock Soars To Nearly 3-Year High On Buyout Buzz, Retail Sentiment Rockets

Reuters reported that German healthcare and technology group Merck KGaA is in advanced talks to acquire the company.

Springworks surges as Germany's Merck KGaA said to be targeting takeover

Investing.com -- Shares of Springworks Therapeutics (NASDAQ:SWTX) surged over 37% on Monday following reports that Germany’s  Merck  (NSE:PROR) KGaA is in advanced talks to acquire the U.S. biotech company, according to Reuters.

Springworks Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the application of a medicine approach to acquiring, developing, and commercializing medicines. Its pipeline includes Nirogacestat, Mirdametinib, Brimarafenib, SW-682, and EGFR Inhibitor. The company was founded in August 2017 and is headquartered in Stamford, CT.

SWTX
SpringWorks Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest SWTX News

SWTXSpringWorks Therapeutics Inc